Future research could focus on developing specific GPR30 agonists or multi-target drugs that jointly regulate the BMP-6/HEP/FPN pathway for the treatment of osteoporosis and other ferroptosis-related diseases. The gene discussed is BMP6; the disease is osteoporosis.